Rise In Air Pollution Driving The Growth Of The Market Due To Increasing Health Risks And Demand For Targeted Therapies Is Supporting Development Across The Respiratory Biologics Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Does The Forecasted Market Size Of The Respiratory Biologics Market Compare Between 2026 And 2030?

The respiratory biologics market has experienced rapid expansion in recent years. It is projected to grow from $7.41 billion in 2025 to $8.61 billion in 2026, achieving a compound annual growth rate (CAGR) of 16.3%. The growth observed in the past can be credited to the limitations of conventional inhalers, increasing severe asthma cases, biologic therapy approvals, improved immunology research, and the expansion of specialty clinics.

The respiratory biologics market is projected for substantial expansion over the coming years. This market is anticipated to reach $15.66 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.1%. Factors contributing to this growth include advancements in precision respiratory medicine, the expansion of biologic pipelines, increased healthcare expenditure, enhanced reimbursement strategies, and addressing unmet needs in severe respiratory conditions. Key trends identified for this period encompass the growing acceptance of targeted biologic treatments, the broadening scope of severe asthma therapies, the development of biomarker-driven patient selection methods, a rise in the application of injectable respiratory medications, and a movement towards long-acting biologic agents.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23497&type=smp

Which Growth Drivers Are Expected To Support The Respiratory Biologics Market Forward?

The increasing levels of air pollution are expected to propel the future growth of the respiratory biologics market. Air pollution refers to the existence of harmful substances such as gases, particulate matter, and biological molecules in the Earth’s atmosphere, which can negatively affect human health and the environment. This increase in air pollution is occurring due to rising industrialization and urbanization, leading to higher emissions of pollutants from factories, vehicles, and construction activities. Respiratory biologics assist in combating the health effects of air pollution by delivering targeted therapies that reduce inflammation and improve lung function in individuals exposed to airborne pollutants. For instance, in January 2025, according to the Environmental Protection Agency, a US-based government agency, the United States released over 66 million tons of pollutants into the atmosphere in 2023. Therefore, the rise in air pollution is driving the expansion of the respiratory biologics market.

How Is The Respiratory Biologics Market Distributed Across Key Segments?

The respiratory biologics market covered in this report is segmented –

1) By Disease Indication: Asthma, Chronic Rhinosinasitis, Hypereosinophilic Syndrome

2) By Route Of Administration: Intravenous, Subcutaneous

3) By Sales Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Mail Order Pharmacies

Subsegments:

1) By Asthma: Severe Eosinophilic Asthma, Allergic Asthma, Non-Allergic Asthma

2) By Chronic Rhinosinasitis: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps, Chronic Rhinosinusitis without Nasal Polyps

3) By Hypereosinophilic Syndrome (HES): Idiopathic HES, Lymphocytic Variant HES, Myeloproliferative HES

Which Trends Are Contributing To Changes In The Respiratory Biologics Market?

Leading companies within the respiratory biologics market are concentrating their efforts on advancing novel biologic treatments, such as targeted immune therapies for chronic respiratory diseases, with the goal of delivering precise care to lessen inflammation and improve lung function. These targeted immune therapies for chronic respiratory diseases are interventions designed to help regulate the body’s immune system, thereby reducing swelling and alleviating breathing difficulties in persistent lung conditions. For instance, in September 2024, Sanofi S.A., a pharmaceutical company based in France, announced that the US Food and Drug Administration (FDA) had approved Dupixent (dupilumab) for use as an add-on maintenance therapy for adults diagnosed with chronic obstructive pulmonary disease (COPD) that was inadequately controlled and presented with an eosinophilic phenotype. This authorization signified a major milestone, establishing Dupixent as the inaugural biologic medicine approved in the US for treating this specific population of COPD patients.

Which Organizations Are Involved In The Respiratory Biologics Market?

Major companies operating in the respiratory biologics market are Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Amgen Inc., Swedish Orphan Biovitrum AB, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb Company, Johnson & Johnson, Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Glenmark Pharmaceuticals Ltd., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc.

Access The Complete Respiratory Biologics Market Report:

https://www.thebusinessresearchcompany.com/report/respiratory-biologics-global-market-report

Which Region Stands As The Largest Contributor To The Respiratory Biologics Market?

North America was the largest region in the respiratory biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Respiratory Biologics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=23497&type=smp

Browse Through More Reports Similar to the Global Respiratory Biologics Market 2026, By The Business Research Company

Respiratory Devices And Equipment Therapeutic And Diagnostic Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-and-diagnostic-global-market-report

Respiratory Devices And Equipment Therapeutic Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-devices-and-equipment-therapeutic-global-market-report

Respiratory Disease Testing Market Report 2026

https://www.thebusinessresearchcompany.com/report/respiratory-disease-testing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795